Success through focus

8/7/2019 Success through focus

1/60

SucceSS through FocuSt ga g 2009


2/60

2 | G r n e n t h a l G r o u p 2 0 0 9


3/60

AnnuAl review 2009 | compAny portrAit | mArket And BuSineSS development | core BrAndS | reSeArch & development | 3production | grnenthAl AS employer | corporAte reSponSiBility | outlook

tABle oF contentS

Fd by hd F. Sck, pD.,

Ceo f G G ............................................................pg. 4

a rvi 2009 ........................................................................... pg. 6

Cmy pi 2009 .....................................................................pg. 10

Mk d Bsiss tds 2009 ....................................................pg. 18

C Bds 2009 ..............................................................................pg. 24

rsc & Dvm 2009 .........................................................pg. 30

pdci 2009 ...............................................................................pg. 40

G s emy 2009 ..........................................................pg. 48

C rssibiiy 2009 .........................................................pg. 52

ok Ssibiiy g

Cid Fcs ..............................................................................pg. 56


4/60

4 | G r n e n t h a l G r o u p 2 0 0 9

hArAld F. Stock, phd., ceo oF the grnenthAl group

da las a g,

ga s . ts f s saz as 2009q . d a s a s s a

a faa a x a aas f a f bassf - f sss f a. F gas s -

aaza, a saz sa as Sss Fs. pa f aa a s a a b a as a a

a s a asa. ts, a saz s aa ss f as a f 2009 s a a a bf bsss a f 2010 a sa .

w a ga g s ss a abs a 2009: w a b ba a a a aa x f as. w a

ass a a a s a a b f 2009 a10-ps pla a sh-, - a l- ass. ths la s h

fa s a a a ss. B s a,

b a bass f a sa ass b aa x a sss as as f a .

w a aa a a a x s a q ssaab a as a a fsab f. w a aa

s a a a a ss ss gas fs a a. ts as a ff f a. w a a sssf bsss a ba a a l aha h f h s. wha s hs f bas ?

ghal s s h aas hh a a sssfl r&d fs haa-

a a: fab a a. ts ab s s as as as fab a a ss s a, a sa f

fs a aa s s a x, ff f aa f sa a . ts s s a a a a a a

a a as a fa- a.t bfs f s a s: w a a a -

a a sa a js a f f.tay, ghal s f js f r&d fs haaal as h a

aqas ga. B a s a b ff: s

all a h, l fs hay ss, a s a hhs b s a a s b f a aaa s as xss a sa as as a, sf a a

s. A f s qs s b fxb, b a a a a a .


5/60

F o r e w o r D | 5

wa s s sfa a f ga? o as s a a a-s ass a sfa a f as. t as

b a a a ff a sssf. w f ba b s sssf a s a a a s: o a sbsa

aal, hh as alay h uS 2009, ll a a s b

as a a f a s a.

w s ass ssb f as. B as a a f f baas s a. ts s ga as a s fv ps glbal Ssaably a chf cla off, h s ly h

ceo. ts s as a f a: a sa as a f as s, a s a as as af js sa f s aff a a as.

o s h fl f a a h lh f las f h f. B hy a

ss f sa. w b a s sa

ab s ssaab a aas s a a fsss as a ga r&d fs aaa a, a a

ss aa s bas f s:

1. ia- a as a aa2. g as3. m f axz

4. ta fs f bsss (a s, fs f aa bsss s)

o sas, Ss Ba a ga maa f b a

a s xa -q a a sssf f f sf. i ss, s a a a bab f a. y ,

a a sas f ga s a s b a f as sss. F s as, s a bs a

s f lys ass ssbly, aa a b a f h sss.

w s , a f s s ga b s

l ay a a s. w l fa a a al h y.

haa F. S, pd.


6/60

6 | G r n e n t h a l G r u p p e 2 0 0 9

AnnuAl review 2009


7/60

AnnuAl review 2009 | compAny portrAit | mArket And BuSineSS trendS | core BrAndS | reSeArch & development | 7production | grnenthAl AS employer | corporAte reSponSiBility | outlook

Q1 JANUARYFEBRUARY

MARCH

1s QuArter

Sa: Aa f ia pa exo tas a a as as as b f s a as

as 25 as Sas aa p esa esa 25 Asa.

pa: pa rf iao ps affa ga S.z. a a a f a aaf h plsh Assa f h Sy f pa. i a ll-f lh sla,

ss a a s a a a , a as td w rs pa as a. t s f

aas wasa Fba f 2009.

cab f is a c hs Sxv g ga Aso ma 20, 2009 cab f is a c bs aas fh fal xaa l sx as a ghal. ths ss as

f -qa, -f a ga s.


8/60

8 | G r n e n t h a l G r o u p 2 0 0 9

APRIL

MAY

JUNE

JULY

AUGUST

Q2

Q3

2 QuArter

Aa f Aa f taa euga f aa f eu aa f sbsa aa f

a a a. taa s a f gas sa.

i f a n ca Sga a a s ma 1, 2009

b sssf as a , fa- ga a. ca ssbs as f s s s a aa s-a.

Sza: g S Aa f p cas AgF a , Js&Js p cas Ag, bs

ga Sza , as s bs a s gS Aa. t sas s s aa Js&Js aas.

3 QuArter

uSA: i f na

t sbsa aa, s f gas sa, as b a uSA b a a Js&Js ba a na sJ 2009.

o wa a ga pa wga ss a fba f s s. F

s as, ga a s fs- s a ga pa w s.


9/60

AnnuAl review 2009 | compAny portrAit | mArket And BuSineSS trendS | core BrAndS | reSeArch & development | 9production | grnenthAl AS employer | corporAte reSponSiBility | outlook

SEPTEMBER

OCTOBER

NOVEMBER

DECEMBER

Q4Sssf eFic pa cf lsbga s as iii aa a sbsa aa a 6

f f ea Fa f cas f iaa Assa f S f pa (eFic). t sf ss aa as a b sss a 700 aa sas.

4 QuArter

n o f ca ci ob, ga gs ca ex Ba zaa f a ca c Aa-ef. t ca ex

Ba a s, as bfs a f asa, ss a q ss.

70. Aa hs m a gaiaa xs f aa a sss aa a

e pa Bs as a ca ca ds as ao.

Ba eq Sth ghal g lah h Ba eqy pj a h f 2009 asss

a s a as as a. ts as fa f a f ga g.


10/60

1 0 | G r n e n t h a l G r o u p 2 0 0 9


12/60

1 2 | G r n e n t h a l G r o u p 2 0 0 9

Grnenthals Strategic and

Operational Direction

ca pa 2009

ga s a r&d fs aa -sz fa- a aaa s. o s a aa a a fs

a f a s a, a f b ba fa a f as, a-a-fssas a as. w s asss asl la a slf- lf. Aal fls f hay l f-

a s a s. A b f 2009, a 10-pspa ssaab as ss a s, a -ass. th a ass alay l a h b f 2009 l

sabs f s, a b- fa a-s, a s a a ba as a bjs ss. i s ,

a s a a b b as f a, a aa, xas ba a s a axzs

sss f ba bas. F , s a ssaab f s f s a sbsq ss as, a ff asa asa as as a ba a f ff a a

a sbsa aa. A f 2009, as ba f a a sa f ga as a - as. i s

f bsss sb, a as aa f ss, f s as a fs a f a a .

t gba ca oas (gco) ds ss a, a-

aa f a a sb as s gas s b azas f s .

t rsa, d, ra Affas, pa, pf maa ad, a Bsss d & lss a b gba ps

(gp) ds.t a aas a , qa, s a, a s

as a gba oas (go) ds.

th gal & Asa (g&A) ds asss all aaal a a-safs.

o h ll, a fs lbal bas a h a- a-

. i a a s taa, Zaa, tas a vsas, babas as a a Baa as as cs / cs cF, asb sssf as s fbss a f sa as.


13/60

AnnuAl review 2009 | compAny portrAit | mArket And BuSineSS development | core BrAndS | reSeArch & development | 1 3production | grnenthAl AS employer | corporAte reSponSiBility | outlook

Corporate

Excecutive Board

Corporate Governance

Jahresrckblick 2009 | Unternehmensportrt | prodUktion | prodUktportfolio | lagebericht 2009 | forschUng Und entwicklUngmitarbeiter / personalpolitik | Unternehmerische VerantwortUng | meilensteine der firmengeschichte

haa F. S, pd. (s f f), s cf ex off (ceo) f gag. wfa B ( f f) s a f a a sas as

. Sfa g (.), cFo&coo, aas gba Fa, gba c,ca la, gba it, gba isa oas a gba S ca maa-

. pf. e-pa pqs, pd. (.), s ssb f gba ps s, ..f f, .. rsa a d as as wAas a pa.

ga as f b ha wz 1946. As f 2009, s a b 20

shahls. th ay s by a ca ex Ba f f, hh s ha by

ceo f ga g. t Ss Ba ss a af ga g.

as & s

ShAreholderS

SuperviSory BoArd

mAnAgement


14/60

1 4 | G r n e n t h a l G r o u p 2 0 0 9

internAtionAlity, SucceSS And innovAtion

Internationality

(As of 2009)

Success

w a s b affas 35 s.w sx s.

w ab 4,900 s .

ga ba aa as a . o a as aa x-

abs Bl a h nhlas ly h yas af b f. tha sa ffs aba sabs sa 1950s s sas Sza a Sa. w a s s aa aaz

a s fs affa as sabs p 1968. ta, gas s affas 35 s a as ss sx s. o

s a aaab 100 s a axa 4,900 s fga . B ga a aa as : t2,000 s bas ga f 34 ff as. ga as b a

b f ca f ds f ga cas s 2009, a s s a a s, a a qa s f a f s s.

w s aa sb f s asa ga 2009, js 80 % f as a b ea a

la Aa affas.

w a as bf axs b a 50 % as

2008. i s f h saly as ss, lys ha s

sas 2009 as . na a f aa azas

bsss a a fas a s as.w a z ba a j f 2009 a

20 ass a sa as.


15/60


o lys a h y sss. w a al sfl a a-

a. o f as s a a b js s, bshl b fala a l by y ly. th py pl, h tasay

pl, h dla pl, h cla Aably pl a h J osh

p sa f s s aaz a a a s f a a.

w aa, a a a a , as

s q aaa f ass f a, s fs bf aaa ass mor-nri.

i 2009, s 18 % f s (157 m ) sa a .

22 ea a 16 uS as aa s ffs s f as f sa a .

A 60 as a, ga as fs ws ga a asb . A f as a, taa, s s sb a aa l h js a sbsa, as h a. th l

a f tas, f fs a as, as sssf a 2001. ga sas f a as a b, ff a

f s-ffs. t as s, s 18 % f sas sa a 2009. A xa f gas a sa s

f a ta rssa Fa (trF), a f f ab ass ala a as h a sably ffl abs has

s aa sab a sb.

Innovation


16/60

1 6 | G r n e n t h a l G r o u p 2 0 0 9

grnenthAl AFFiliAteS

gaaffas

pa s

Asaa

AsaB

Bsa-hza

ccbacaa

cz rbdaea

FaFa

gaia

ials

mxnas

napaaa

ppapa

rssaSaa

SaSa

SSza

tua

u kuSA

vza


17/60



18/60


19/60


mArket And BuSineSS trendS 2009


20/60

2 0 | G r n e n t h a l G r o u p 2 0 0 9

development oF the world phArmAceuticAl mArket in 2009

t a s a aa b -a qa f 2008 afa

f faa ss. ia a f s, ss a s a a

s as, sfas a s a xa

as. i s f ass a b sf a s, sa 2009 as asaff b faa ss. h, a s ab aaa s as f , s

a a f a s a f a s a s b sa a-

a sss. B a aa f sa a s a ss aa ss

f.t aaa a s s aaz

b a aa s f b s, as f a a s f xs

as s, as as b a s as- a f as. As s, s - sa f fs

a aa a b f b s.t aaa a a uS$ 726 b 2009, s qa

f s a. w a a sa f 41 %, uS aaa a

as s a s , f b e. t sa f aa-a a ga as 5 % f a.

w a a f uS$ 31 b, a/aas a as as a as

yas ll h h l haaal a; h sha f h all a

as 4.3 %. t aass s, s f a ga a a, aa a a f 9 % (10 % s a).

w aa a s f aaa a f s f s ss f s a s, as bas f a a , a s as as as

s h aalably f haaals a a s. w

aa a a f a as 5 % a, aa f f a. tsb-ss f aass a - s a a sfa b s .

Source: IMS World Preview, March 2010


21/60


22/60

2 2 | G r n e n t h a l G r o u p 2 0 0 9

o bsss a 2009 as aaz b a f 17.3 m 2.0 % as a s a a a f 36.2 m ss

a s a.c s s sas s a s f ss s

ss. i ss, e b s sfa a

a a sa f f 80.2 %. t Aa a a 86.9 % f f a s f e, a 19.8 %.

w gba ca oas, -s taa sff

sss f 8.8 %, ba Zaa j f 15.7 % a b a as tas a nsa a as a 4.3 %. o a

a vsas, as ff b s a, as b s a as f 60.4 % f s as s.

i a, b a as a a sa f 14.3 % f a, f b Zaa 12.7 % a taa 12.5 %.

w a 8.6 % f s Baa , s a 3.6 % as a s a.

t sa f ba bas s as 61.5 % f aaas a54.1 % f a .i a bsss ss, s s a a sb a

a, s as a-fs a asa as, s a as f 3.3 % h s ya s ss

f s, fh lsla s ass halha al s

a a ajs as xs bas f za.

t ga s a b as sa f gas sas 2009

155.2 m , ss axa 20 % f a s.t ea as a ga fiba (Sa a pa) sas f 156.7 m , f S e (ia,

Sza a Asa) sas f 118.3 m a Fa, ga a sas a sas f 114.6 m .

gas s u k as as as: a 22.7 m aa f 30 %.

i f ca a S Aa, ga b s f 113.0 m a a qa sasf f 8.9 %.

Products

Countries


23/60


d Saaa s as as s 2009: w a

al as da a S. i S a Bl, aal

f vsas.

i bsss, aas a, gas a a( a bsss) a s ab a f f a a a x1 f 102. i ss, ga s sabs sf a

f a ss s ga as (ab a e) a a sa f 11 %.

i s f as a, a as as a Sa a czrb, a xs a-a ss B, pa a S-

a. t a f ss as a f fs u k.

ghal s a ffh la a l a h sb-a f ally-

a aass ( a - s) a a sa f 4.1 % (2008: 6

a). i e, ga s f s s aa sa f 13 %.

1 The evolution index compares the growth of a market participant or sub-segment with the growth of the

market in which it operates. An evolution index of over 100 indicates above-average growth of the market

participant or sub-segment, while an index below 100 indicates below-average growth.

Market Shares


24/60

2 4 | G r n e n t h a l G r o u p 2 0 0 9


25/60


core BrAndS 2009


26/60

2 6 | G r n e n t h a l G r o u p 2 0 0 9

core BrAndS 2009

na 20 % f ea a sffs f a, ss as b f ss aff a fas.

ga sazs a a a ss qa f f fs aff b ff a ab aass. ga s ss

b s s sa f a as a b, ff a

f s-ffs.w a assa ab ba b f a a aa f

as, a-a-fssas a as. gas f ss a ab f ff a s f as as a a s.

i ffs ss f a fs f a s ass f a a a (.. aff a aa a f b) ss, a a a

sb hh h by (s aa bl). i a hs a

f, as sssf a as s 2009. o sa aaab a 100 s.

3

2

1paInI

ntenSItY

aCute ChronIC

SYSteMIC topICal

ChronIC

oa: Zaa taa tasa: nsa/ tas vsas


27/60


taai 1977, ga s a s a a f taa

(aa ). taa s a a a aas f a as s a. ta, taa a as bas aa a a

s fq s a aass f sbsas as a

a as, a a 10 b a 100 s. tsss bs aa a as f aa a aafssa assas.

Sss f gas sama : 1977

Sas 2009: 143 m

tas/ tas pi 2001, ghal ba h fs haaal a a asal

ax a: tas. t a sbsa s s b.

Sss f gas a ma : 2001Sas 2009: 103 m

ZaaZaa s a f - aaa a a aa, sb - a aas a sbsas. i s a f a f a s s a.

A ba f a sbsas: aaa a aama : 2003Sas 2009: 146 m


28/60

2 8 | G r n e n t h a l G r o u p 2 0 0 9

vsasvsas s a a sbsa a 5 % a f a a asaff f aas af s zs fs (ss).

exs a ff a a ama : 2007 sx eu s, ca a S Aa a rssaSas 2009: 28 m

nsansa s a 7-a a a a sbsa b. i s s f a f a, -aa a.

l sa b a ama ga: 2007Sas 2009: 21 m

BaaBaa s a a a a as b a f 10 as. ta, ssb ab 40 s .

oa ama : 1999Sas 2009: 78 m

NORSPAN


29/60



30/60

3 0 | G r n e n t h a l G r o u p 2 0 0 9


31/60


reSeArch & development 2009


32/60

3 2 | G r n e n t h a l G r o u p 2 0 0 9

reSeArch & development 2009

ga s f as f sa- aaa as a-qas bas ga ssaab ss sa a . ts

ss a 18 % f s 2009. ghals sah a l

say as sl fls f hay a sa-f-h-a hls. w fs

s sa f as a a b, ff a f

s-ffs a bf.

Grnenthal's Research

& Development Centre

Preclinical Research and

Development

o rsa & d c s a a aqas Aa (ga).Axa 650 s a r&d aa (. pa r&d,

ca d, ra Affas, d Saf a s s). r&d s a fs a, a a a s, a as f faass.

o a sa a a s as 2009

f s b a - ass f a f a f a. effs b fs sbsa f a a f nces (

a s) a a a aa sssf 2008. ts s as afa 2009 a s sbsa f sa ass f nces.

a

ax a

preclinicAl r&d

pAin

clinicAldevelopment

drugApprovAl

a a aass

a a aass

therApeutic AreA vAlue chAin


33/60


ga cas Aa (2009)


34/60

3 4 | G r n e n t h a l G r o u p 2 0 0 9

t ss f , -aa a a a a a f nce j aa a q s a

ss f ea sbss, a sssf sbsss e fb f s as A 2009. t aa nce-sbsas f ss f

a nce-a a a as: t fs sbsa s

a as iia a f s-a f f f sas-sf ff as, s sbsa f s a s s a aa as.

Sbsss f a paxa a A 2009; a, 122 a-

al alas sb 38 s. i h uSA, a Jhs&Jhs

has alay la h s a sbsa aal f h a f a

a a ba a na J 2009, a a aaf a a a as a c db 2009. 29 aa s

a 2009 f a a vsas as ea s as as na eas; ea aa as aa sssf

14 s as a as db f 2009, a a 35 s a .F, aa s f a s, as a f

ms a b sa ea a 17 s. 16 aas a f a fa f ba Zaa as a

ffs ab ba a Zaa ffs. i 2009 a, 21 aas f s f as e. t as 18

aas f s eas e, ca a S Aa, Afa a na eas.

22 ea a 16 uS as aa s ffs s a sa

f as f sa a .

Clinical Development

Approval, Patents

and Licenses


35/60


i a a a, a as a - z ba j a f 2009 ass

a sa as. w a a a f 20 as ba , s a f a:

1. d a ma ca f AxaAxal s a a a sbsa a s f ghals l l.

i s ly lal has ii a ss a h, aly s s

a a a a abs.ga s f sa-a f f axa a

as s uS a e paaas i. a s a f a a.

2.ls A f trF t (ta rssa Fa)

gas trF (ta rssa Fa) as ssb f abs as x ssb aa sab

a ab sb. ts aa sab as a baf sf xs a q afa . A aa a as 2009 a a ga a a a s

uS a s .

3. i-s A da-ras F f Zaa

w a a a a laba e l a ga a a f s f f Zaa s eas.

4. taa exas Sa ega as s a - a f s s e a baa a a f s a a a .


36/60

3 6 | G r n e n t h a l G r o u p 2 0 0 9

tApentAdol

A ally a aals s h a l h f f aal, ghals

s a. tas s q aaa f ass

f a, aa s fs b f a aaa ass

mor-nri : i bs - as (mor) h aal a hb (nri)

a s . taas as f a s a ss f a

f ass s, s as x , a a a aass.

p-lal ss a ha bh hass b aals aals ff.

2 mcisms f ci

i 1 civ sbsc


37/60


DEVELOPMENTAL PHASES


38/60

3 8 | G r n e n t h a l G r o u p 2 0 0 9

Project Indication Phase

taa

a uSA a a

taaa eu

a a

taa uSA

a

taa eu

a

taaJaa

a & a

taa lcma & a

vsas lcm a a

Axa

-

aa a

Axaa a

nce 1a & a

nce 2a & a

nce 3a a

our pipeline the engine oF vAlue creAtion

AaSb-ss


39/60


ghals lbal lal l as s f a

a. ts s a b as b a a f as (nces) a f ghals lal sah. i a, sa-

f--a as (ntes) a aa s f sabs sbsasa b l xa h fl. i ghals , a bala l s h

f a a. t a s a sbsas a basf a sbsas as sas f .

Our Pipeline

the Engine of

Value Creation


40/60

4 0 | G r n e n t h a l G r o u p 2 0 0 9

ga a Ja 2009 s usaz wssa b 3% (xx) af 864 m e s (2008: 846 m. e). i ea b

as usaz-was 2 %. ca: Za, imS?

g ghal nlass usaz 155,2 a gshfsbh

dsa, f f 20 % ss gsasazs vb Az s.

d m f ga ea a ab as r iba(Sa pa) usaz 156,7 , r Sa (ia,

Sz s) usaz 118,3 Fa, gas pa usaz 114,6 z .

eflh a ah as ebs ghal gba, 22,7 sz

was 30% .

i r Zal Saa zl ghal usz 113,0

bfas f was 8,9%.

ga as was sbs s paa iasf

Sz. S s a 434 m. e z s gsasaz b. h f asusazas xx% bss as a s as as was s

waaas (xx %). Sss ezaa a (df) taa 161 m.e, f xx (df) Zaa / ix.

i s kshf, Aalaa, la as wahs ghal-Sh-

zal elsx 102 lh b f Shza. dab

a s ga a ea, s maa 11%

t-5 Ab f Sz z ab.

i laf s a Jas b bs bs afps B, p S a mafsaf Sa ts- . i gba sas S t 3

Ab saff.

i ta zasa Aaa (sa sasa o) ga ra maa 4,1% af paz 5 (2008:

ra 6). i ea ga s ps t d maa13% f .

isbs s l f e 2009 s f: i

da Sh sa s zll A. i Sh


41/60

AnnuAl review 2009 | compAny portrAit | mArket And BuSineSS trendS | core BrAndS | reSeArch & development | 4 1 production | grnenthAl AS employer | corporAte reSponSiBility | outlook

ba Zass f s paa vsas. das g f B.A f Zf s iasb Sz b wass-

za s b. w ia z B s p:taa as s Fs 1977 zs dsa as taa

f. m s s , z as 2 m. paba-

lsa s a as s zalsa Aal (msbsaz).da s f gsfs iasb Sz eaaq 47% Ja 2008 af 52% Ja 2009 s .

As afs s as u Fabsz f

Sa, s was a b s Fss- e-sas z s. w ab a A f F&e a 19% A a

kzsaz sa af na a.

d usaz a s 3% Ja 2008 af 8% Ja 2009 fas fa.

production 2009

gas gba oas () a ss

b saf, ab, qa, s-a a ff.o ss sx s fba aa 2009.

i 2009, as a ba sa ss gas ss fs s bsss

f a b a saa sfa -s f a a. w ba s as a f 2009; a b b 2012.

th ly sablsh j aza tasf & Sa-

s ssa a x a -y asf b r&d a p as ll as b h

a ga ss a a afas.o qa aza ss f, s,

a fssa a aa a - a gmp (g mafa pas)saas, as f as a s qafa,

aas, sa a s as.t bab f s a f

ss ga, Sza a ia, ass a a f a sbsas a abs

fa aa, a a q fasssa a s f r&d.

gba S ca s gba oas ma

a dsb a ss s as as as s f f ffs.


42/60

4 2 | G r n e n t h a l G r o u p 2 0 0 9

20 hh-fa aa ls y 6,000 2 a h aa . naly all f

h haaals hh ghal sbs a aa h. i s ly

h sb a h hh-bay ahs. ths ha sal hs f s

a s s fa nas A. ts s gas f aa a sb, a ga s fs a e

a a -ba as a f as. F, a sbsas (sas aa, , bas), a s f gas s, aafa s. t s ff b s f

afa s as a q fs as as aaa s

as s as abs a -sa s. t fa s f aa en iSo 14001 a ohSAS 18001.

Location Germany:

Grnenthal GmbH


43/60


w a aa f 50,000 2, iaa fa o (a ma) s f

s aaa as. t fs f iaa s saaa fs f a asa. t a as as a fa f f a ss. t fa s f aa en iSo 9001:2008.

t s ffs a ba a f ss, aaa , - (afa a aa), qa aza, aa a

sa.th haaal l has a flxbl a qalf aza f all as

a s s as -fa ss, fa , aaa

s, aa as, sab ss a f a ss.

Location Italy:

Grnenthal Farmaceutici

Formenti S.p.A.


44/60

4 4 | G r n e n t h a l G r o u p 2 0 0 9

msa fss a xs a f aaasf aaa as. msa js a x a a s

ss f b s-, ab a . w s sa-f--aq, msa ffs a s a f ss, sa aaaflas a aalyal l a h s f lal ss, sal

las a afa a saas, l all qs

s a qaa ss. i a abs a ass, s sh afa f , alas, lls a -abls as ll as haaal

f as.

Location Spain:

Medinsa (Laboratorios

Medicamentos

Internacionales, S.A.)


45/60


Location Switzerland:

Grnenthal Pharma AG

Proto Chemicals AG

ga paa Ag s f afa f s-saaas ga .

os, as, s, s a sss a afa s ohSAS18001 a iSo 14001 f fa. i s q saa sf a abs a s. t -a sss a

sas a ba- sss a SAp-s a pa 11-a. tsas ssb a aaas a a b f a

sbsas s as s, abs, as a as f a.o ss a s ss s f s a, sa

a a a a .

ga s a sbsa aa a fa b sfaf s s a p cas Ag m, Sza. i bs a

a sbsa fa - x a a xs aa. p cas Ag s a b FdA as as Sss m a f

aa iSo 14001 a ohSAS 18001.p chals Ag s h la sl f h a aal l.

t a b f ss s a aaa as ff a a s.

t a s a a s a, s, qa aab f s sa f xa b fa a Js&Js as

p cas Ag as s fs Api s g S Aa s a .


46/60


47/60


Location Ecuador:

Tecnandina S.A

taa S.A. s as a s fa f s a s-saaas ea. i s gas a fa, aaa

a ss b la Aa. taa s z as f a afa a ss s, a s ss baas. w a aa f 50,000 2, a f Q aas saas f qa ga s f s a

aa fas.


48/60

4 8 | G r n e n t h a l G r o u p 2 0 0 9


49/60


grnenthAl AS employer

da a s a a sa fas f ssaab sss f a.i s s sss, s b ab s a aa a a b ass qa as. w s a ga as a s f s fa a as s abs a.A f 2008, ab 2,000 s a ga g ga a axa 4,900 .


50/60

5 0 | G r n e n t h a l G r o u p 2 0 0 9

th f lys s h bass f sss. F ha as, a g-

a f s as a s a

as. w ff ab 70 ff a a ssss a a a s qafas: saz, a aa a ss as as

sas fs bhaal a, j aa, pc a a aa

a.w alz hs hlshy h a , ahal fa ca c

Aa-ef, ss aa a . i ffs a abas,

a a s, a a s, sx asss f as, 18 sa sas as a s.

i f as, affas sas a as a a. i s a a aa bsss a

a f as a aas s as a a s xas a a a a f s.

i 2009, a aa a f aal aas as sablsh f h

fs . i as s f fssa aa a ga, bs

fa--fa a a -bas a, a s a asf as s fssa a f as a aa.

S s sabs 1946, ga as ab 1,700 as a a -

f a a-bas fssa f. m a af f sa b aba as a sa a qa azas,as as a qas f a as

a a ga. i 2009, ga as ab 30 as ss fsss: a a, s aba a, b aba

ha, sal bsssa/a, bsssa/a f ff a,

it sas ss a a it bsssa/a. Axa 90 aly l h a a ghal. o h xaa has b l

sssf, a a as f a as sx s. ga as sa aa ss a as s f aa as. ga s f as a as Aa aa.

ga ss s a a f s s

fba. w s a a s a ga pa w s 2009: h sasf a s ass a

ga? h ab f sss a aa? h s as as? g fa, as s a

a s aa, s a a s a ga a gapa w. w s aa, sas a f fba

a.

Advanced Training

Apprenticeships

On the Way to a

Great Place to Work


51/60


An wen im aske wa kees

you u a n an wa es you

ou of be early n e mornn, s

exacly a. i wan o make grnen-

al a lace were e bes eole

n e marke say, tas e bes

emloyer a i can mane.

haral F. Sock, pd.


52/60

5 2 | G r n e n t h a l G r o u p 2 0 0 9


53/60


corporAte reSponSiBil ity

As a lbally a, faly- ay, g-

a s aa f s a ssb. Ssaab -

a a s a a a saas a s a ssb. ts,

s a a aa fas a ssb a a

as a a a a s.t f a as b a s ss

f ssb. ta s a s b a f

as s. i sa, g-hal s a s al h h sas

f s aff. o s f s a: i J f

2009, ga gbh a a a s f 50 m ta Fa.

w as b b a sa

f aff f. w s f sabjs h h h ss aff alsh

s.

w a a a a a f a - a ss-aab as f f a f a as. w a

assa a ab a a-f a sf-f a a ss a a a sfa a sa.


54/60

5 4 | G r n e n t h a l G r o u p 2 0 0 9

ga sabs ga Fa f paa m as a as 1998.i s a s f ab sss a a f xa.

t fa s s a sa aa caf paa m a Aa us. i ss a f s a .

t a s aa qa f f a f s aff as as

f s.

i 2009, ga sa a aa a a chAnge pAin as

a sa f s f as s a a ss a aa. ia b ga a s b

ea Fa f iASp cas (eFic), a s a xsf ass e. t aa As Ba s a b pfss gs va-

ass, md, ps f eFic, a d. ga h. h. m-Sf, md, ps f ga pa Assa (dgS). k bjs f chAnge pAin a a ab sa f hysas a as ss, blsh h sls f sah

js a a fs sf blas, as ll as as l

f a s faa a a ss.chAnge pAin s a s b ss f

aa fssas f a a. pAin educAtion s a aa afs ss s f ssss f chAnge pAin . t

pAin educAtion a s s aa fssas --asf - a s xs a s b -s a aa b a a as-a a

aa. haa fssas a aq cme (s a a) sb aa a s.

S 2004, ga as b s sss az a a

a xa a sa js a ea Fa f

cas f iaa Assa f S f pa (eFic). t eFic gaga (e-g-g) s f s sa zs f f a a a s f 200,000 .

Engagement in

Palliative Medicine

Change Pain

EFIC Grnenthal Grant

Pain Research Prize


55/60


ga as b a aaas f a as b

b s, b a ass .p as ff a s f aa sass

a ss aas f h l. F ha as, s h -f aza-

a , a a x a aaa as.

w aaas a . t, a sa, q aa ss es, F Sas a s a f ssa s a q.

o a a as s aa who s faaa s a b g ds da pa (gddp).

th safy a halh f ss, lys a hbs, as ll as h

f a f a a ga. F a as, sa f a saf a a a a a f s

f ga. ga as sabs a ba ab a aaa sys alsh hs. th safy f as, hbs a lys

hs as fs y f ghal. w a aal s, as

a sa y a a by sly hs a sss. By

hs sys, h ay s fa halls hh x h lal ss

f sa a . o as ga a Sza

s a a a ab fa aa saas iSo 14001 a ohSAS 18001 f a as. w a as a ffs s fa f as. i a, a b aa

rssbl ca a f h s f h hal sy f ay yas.

Aid for the Needy in the

Form of Pharmaceutical

Donations

Consistent Environmental

and Labor Protection


56/60

5 6 | G r n e n t h a l G r o u p 2 0 0 9

outlook SuStAinABility throughcontinued FocuS

o u t l o o k


57/60


58/60

5 8 | G r n e n t h a l G r o u p 2 0 0 9


59/60

| 5 9

SucceSS through FocuS


60/60

Documents

Success through focus